Market Overview

UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy

Share:
Related AMAG
9 Stocks Moving In Today's After-Hours Session
Top Performing Industries For March 31, 2016
AMAG Pharmaceuticals' (AMAG) CEO William Heiden Presents at Deutsche Bank 41st Annual Health Care Conference (Transcript) (Seeking Alpha)

Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation.

In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we believe the Company is undervalued at these levels. Our valuation method which renders a 12 month PT of $15.00 (Table on next page) does give some credit to the potential impact of label expansion but takes a conservative approach to valuing cash (we use cash by YE-2013) and uses conservative revenue multiples (2.0x)."

Ladenburg Thalmann has established a $15 price target on AMAG Pharmaceuticals, which is currently trading up $0.62 from yesterday's $12.54 closing price.

Latest Ratings for AMAG

DateFirmActionFromTo
May 2016Raymond JamesDowngradesOutperformMarket Perform
May 2016Leerink SwannMaintainsOutperform
Jan 2016Northland SecuritiesInitiates Coverage onOutperform

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: Ladenburg ThalmannAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (AMAG)

View Comments and Join the Discussion!